Zacks Investment Research
20 Nov 2025, 15:35 UTC · 43w ago
Verdict
Headline takes no side. We score CNMD +0.60 across four claims — strongly bullish.
+0.60strongly bullish
More positive than 70% of ticker scores this week
What the story claims
4 claims · scored −1 bearish … +1 bullish
Conmed (CNMD) has a Zacks Rank #2 (Buy), placing it in the top 20% of stocks based on earnings estimate revisions and EPS surprises.
More positive than 76% of claims this week
Wall Street analysts have raised the consensus EPS estimate for CNMD by 0.6% over the last 30 days.
Continue reading
5 related stories
Scored by the NIS engine · methodology.
Top 1 mover · tap to explore
More positive than 62% of claims this week
CNMD is currently in oversold territory with a Relative Strength Index (RSI) of 29.21.
So whatAn RSI below 30 indicates the stock may be due for a technical rebound after heavy selling pressure.
More positive than 49% of claims this week
CNMD's stock price has declined by 16.9% over the past four weeks.
More negative than 66% of claims this week
Which stocks this story touches
More positive than 70% of ticker scores this week
The stock is identified as oversold with positive earnings estimate revisions and a Zacks Rank #2 (Buy).
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
Zacks Investment Research
3d ago
+12.1%
Price agrees with the score
$45.42 vs $40.51 close before publication (Nov 19) · not market-adjusted
CNMD chart →
